Safety and efficacy of gefitinib for treatment of advanced non-small cell lung cancer / 中华肿瘤杂志
Chinese Journal of Oncology
; (12): 66-69, 2007.
Article
em Zh
| WPRIM
| ID: wpr-255721
Biblioteca responsável:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the safety and efficacy of gefitinib as second-line or even third-line treatment for previously treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).</p><p><b>METHODS</b>156 patients with locally advanced NSCLC which were about to undergo progression after previous chemotherapy were eligible for this study. The regimen was oral intake of gefitinib 250 mg once daily in the morning or afternoon until the disease progression or toxicity has become intolerable. The drug was provided by AstroZeneca Company by its Expanded Access Program.</p><p><b>RESULTS</b>154 such patients were evaluable for response and toxicity assessment. The overall rate of objective response and disease control was 28.6% (44/154) and 89.6% (138/154). The median duration of response was 7. 5 months. The median time to disease progression (TTP) was 5. 1 months and the median overall survival time (OS) 10.0 months. The actuarial 1-year survival was 41. 0%. The response rate in adenocarcinoma was significantly higher than that in squamous carcinoma (P = 0. 026). The risk of disease progression in patients with squamous carcinoma was 1. 7 times as much as that of adenocarcinoma patients ( P = 0. 011) , and the risk of death in male was 2. 0 times as much as that in female ( P = 0. 002). At least one of these adverse events would be observed in 40.9% (63/154) of these patients, which, however was mild and reversible. Conclusion Gefitinib is effective and safe as a second-line or third-line treatment for previously treated patients with locally advanced or metastatic non-small cell lung cancer.</p>
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Patologia
/
Quinazolinas
/
Indução de Remissão
/
Carcinoma de Células Escamosas
/
Adenocarcinoma
/
Fatores Sexuais
/
Resultado do Tratamento
/
Carcinoma Pulmonar de Células não Pequenas
/
Progressão da Doença
/
Usos Terapêuticos
Limite:
Aged
/
Female
/
Humans
/
Male
Idioma:
Zh
Revista:
Chinese Journal of Oncology
Ano de publicação:
2007
Tipo de documento:
Article